Jenny Chang, MD, is the Dan L. Duncan Professor of Medicine at Baylor College of Medicine and medical director of the Lester and Sue Smith Breast Center. Dr. Chang is widely recognized as an authority on prognostic and predictive markers for breast cancer and is the author of numerous publications in the field. Recently, her work evaluating the gene expression of breast cancer stem cells was cited in The Economist. Dr. Chang earned her medical degree at Cambridge University in England. She completed her fellowship in medical oncology at Royal Marsden Hospital in London, and a research doctorate from the University of London. Dr. Chang is board certified in the U.K. and the US.

Dr. David Tweardy, M.D.

David J. Tweardy, MD, is chief of the section of Infectious Diseases, and a professor in the department of Medicine. He is board certified in internal medicine and infections diseases.

Following undergraduate studies at Princeton University, Dr. Tweardy earned his medical degree from Harvard Medical School, Boston. He completed an internship and residency in internal medicine and a fellowship in infectious diseases at Case Western Reserve University Hospitals of Cleveland, OH, where he was chief medicine resident. He also served as a research associate in infectious diseases at Case Western Reserve University, and as an associate scientist at The Wistar Institute in Philadelphia. Dr. Tweardy’s clinical research interests include the impact of trauma and shock on host susceptibility to hospital-acquired infections and the role of the inflammatory response in infection. His basic research interests include signal transduction events activated in cells and tissues by cytokines, focusing on signal transducer and activator of transcription (STAT) 3.

Michael Lewis, PhD, is an Assistant Professor in the Department of Molecular and Cellular Biology and the Lester and Sue Smith Breast Center at Baylor College of Medicine. His work focuses on the genetic regulation of mammary gland development and early-stage breast cancer, and he and Dr. Chang recently renewed their SPORE grant to study treatment resistant pathways and how to target residual cancers. Dr. Lewis earned his PhD at the

University of California, Santa Cruz followed by postdoctoral training at the University of California, Santa Cruz and the University of Colorado.